Literature DB >> 24599829

Mitochondrial neurogastrointestinal encephalomyopathy treated with peritoneal dialysis and bone marrow transplantation.

Claudia Ariaudo1, Germana Daidola, Bruno Ferrero, Cesare Guarena, Manuel Burdese, Giuseppe Paolo Segoloni, Luigi Biancone.   

Abstract

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare disease caused by thymidine phosphorylase deficiency which leads to toxic accumulations of thymidine (dThd) and deoxyuridine (dUrd). It lacks an established treatment and the prognosis is traditionally poor. We report a case of a young female patient with normal renal function and MNGIE treated by peritoneal dialysis (PD) and allogeneic bone marrow transplantation (BMT). PD was effective in reducing dThd and dUrd plasma levels and in improving clinical symptoms. To our knowledge, this is the first report on the beneficial effects of PD regarding MNGIE neurological symptoms. PD, therefore, should be considered especially in medically compromised patients as a supportive treatment to improve clinical conditions before BMT.

Entities:  

Mesh:

Year:  2014        PMID: 24599829     DOI: 10.1007/s40620-014-0069-9

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  9 in total

1.  Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy.

Authors:  Caterina Garone; Saba Tadesse; Michio Hirano
Journal:  Brain       Date:  2011-09-20       Impact factor: 13.501

2.  Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-up.

Authors:  F Sicurelli; M A Carluccio; F Toraldo; M Tozzi; A Bucalossi; M Lenoci; G Jacomelli; V Micheli; E Cardaioli; M Mondelli; A Federico; G Marotta; M T Dotti
Journal:  J Neurol       Date:  2012-04-25       Impact factor: 4.849

3.  Infusion of platelets transiently reduces nucleoside overload in MNGIE.

Authors:  M C Lara; B Weiss; I Illa; P Madoz; L Massuet; A L Andreu; M L Valentino; Y Anikster; M Hirano; R Martí
Journal:  Neurology       Date:  2006-09-13       Impact factor: 9.910

4.  Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach.

Authors:  J Halter; Wmm Schüpbach; A Gratwohl; M Hirano; C Casali; R Elhasid; K Fay; S Hammans; I Illa; L Kappeler; S Krähenbühl; T Lehmann; H Mandel; R Marti; H Mattle; K Orchard; D Savage; C M Sue; D Valcarcel
Journal:  Bone Marrow Transplant       Date:  2010-05-03       Impact factor: 5.483

5.  Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations.

Authors:  I Nishino; A Spinazzola; A Papadimitriou; S Hammans; I Steiner; C D Hahn; A M Connolly; A Verloes; J Guimarães; I Maillard; H Hamano; M A Donati; C E Semrad; J A Russell; A L Andreu; G M Hadjigeorgiou; T H Vu; S Tadesse; T G Nygaard; I Nonaka; I Hirano; E Bonilla; L P Rowland; S DiMauro; M Hirano
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

6.  Evaluation of gastrointestinal mtDNA depletion in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).

Authors:  Carla Giordano; Giulia d'Amati
Journal:  Methods Mol Biol       Date:  2011

7.  Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy.

Authors:  Massimiliano Filosto; Mauro Scarpelli; Paola Tonin; Giovanna Lucchini; Fabio Pavan; Francesca Santus; Rossella Parini; Maria Alice Donati; Maria Sofia Cotelli; Valentina Vielmi; Alice Todeschini; Francesco Canonico; Giuliano Tomelleri; Alessandro Padovani; Attilio Rovelli
Journal:  J Neurol       Date:  2012-06-19       Impact factor: 4.849

8.  Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis.

Authors:  Halûk Yavuz; Ahmet Ozel; Mette Christensen; Ernst Christensen; Marianne Schwartz; Mithat Elmaci; John Vissing
Journal:  Arch Neurol       Date:  2007-03

9.  Pre- and post-dialysis quantitative dosage of thymidine in urine and plasma of a MNGIE patient by using HPLC-ESI-MS/MS.

Authors:  G la Marca; S Malvagia; B Casetta; E Pasquini; I Pela; M Hirano; M A Donati; E Zammarchi
Journal:  J Mass Spectrom       Date:  2006-05       Impact factor: 1.982

  9 in total
  4 in total

Review 1.  Mitochondrial Neurogastrointestinal Encephalomyopathy Caused by Thymidine Phosphorylase Enzyme Deficiency: From Pathogenesis to Emerging Therapeutic Options.

Authors:  Rana Yadak; Peter Sillevis Smitt; Marike W van Gisbergen; Niek P van Til; Irenaeus F M de Coo
Journal:  Front Cell Neurosci       Date:  2017-02-15       Impact factor: 5.505

2.  Mitochondrial Neurogastrointestinal Encephalomyopathy: A Nonrenal Indication for Peritoneal Dialysis.

Authors:  V S Chandra; B Sanggetha Lakshmi; S V V Padmavathi Devi; N Praveen; N S Sameera; A S Reddy; R Ram; V S Kumar
Journal:  Indian J Nephrol       Date:  2018 Jul-Aug

Review 3.  Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network.

Authors:  Michio Hirano; Valerio Carelli; Roberto De Giorgio; Loris Pironi; Anna Accarino; Giovanna Cenacchi; Roberto D'Alessandro; Massimiliano Filosto; Ramon Martí; Francesco Nonino; Antonio Daniele Pinna; Elisa Baldin; Bridget Elizabeth Bax; Alessio Bolletta; Riccardo Bolletta; Elisa Boschetti; Matteo Cescon; Roberto D'Angelo; Maria Teresa Dotti; Carla Giordano; Laura Ludovica Gramegna; Michelle Levene; Raffaele Lodi; Hanna Mandel; Maria Cristina Morelli; Olimpia Musumeci; Alessia Pugliese; Mauro Scarpelli; Antonio Siniscalchi; Antonella Spinazzola; Galit Tal; Javier Torres-Torronteras; Luca Vignatelli; Irina Zaidman; Heinz Zoller; Rita Rinaldi; Massimo Zeviani
Journal:  J Inherit Metab Dis       Date:  2020-09-08       Impact factor: 4.750

4.  Mitochondrial neurogastrointestinal encephalomyopathy: approaches to diagnosis and treatment.

Authors:  Bridget E Bax
Journal:  J Transl Genet Genom       Date:  2020-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.